Biogen Appoints Adam Keeney as Head of Corporate Development
Biogen has appointed Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development: effective 17 April 2023.
Dr. Keeney will be a member of Biogen’s Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer.
“As we are working to put Biogen on a sustainable growth trajectory, Adam will focus on advancing the company’s strategy and pursuing external collaborations and other growth opportunities,” said Viehbacher.
Dr. Keeney brings more than 20 years of experience leading R&D, business development and strategy organizations at industry-leading companies within biotech and large pharma, most recently as the Chief Executive Officer of NodThera, a clinical stage biotech company advancing a portfolio of NLRP3 inflammasome inhibitors for the treatment of a broad range of inflammatory diseases.
Prior to joining NodThera, Dr. Keeney was at Sanofi where he had responsibility for all of Sanofi Genzyme’s business development activities, including early- and late-stage deals across therapeutic areas and modalities, successfully completing several significant transactions. Previously, Dr. Keeney worked at Johnson & Johnson where he held a number of business development roles with increasing responsibility and started his career at H. Lundbeck A/S.
Dr. Keeney holds a Ph.D. in Neuropharmacology from the University of Nottingham, UK and a Bachelor of Science in Neuropsychology from the University of Leeds, UK.
